Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2008 1
2009 5
2010 1
2011 1
2012 3
2013 2
2014 4
2016 3
2017 6
2018 5
2019 1
2020 4
2021 7
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor.
Wakamatsu S, Jojima T, Hashiguchi M, Kishi H, Niitani T, Sakurai S, Iijima T, Kogai T, Tomaru T, Usui I, Aso Y. Wakamatsu S, et al. Among authors: tomaru t. J Diabetes Complications. 2024 Jan;38(1):108650. doi: 10.1016/j.jdiacomp.2023.108650. Epub 2023 Nov 23. J Diabetes Complications. 2024. PMID: 38035640
Effects of treatment with methimazole on circulating CD4+ and CD8+ T cells positive for programed cell death protein-1 and on subsets of CD4+ T cells in untreated hyperthyroid patients with Graves' disease.
Hirao N, Iijima T, Tanuma D, Ohira E, Kurai H, Shinzawa T, Kase M, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Hirao N, et al. Among authors: tomaru t. Clin Endocrinol (Oxf). 2022 Dec;97(6):841-848. doi: 10.1111/cen.14788. Epub 2022 Jun 17. Clin Endocrinol (Oxf). 2022. PMID: 35692119
Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors.
Iijima T, Hosonuma S, Kurai H, Kajitani H, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Iijima T, et al. Among authors: tomaru t. Int J Clin Pract. 2021 Nov;75(11):e14732. doi: 10.1111/ijcp.14732. Epub 2021 Aug 19. Int J Clin Pract. 2021. PMID: 34388297
49 results